Candriam S.C.A. Cuts Stock Position in Gilead Sciences, Inc. $GILD

Candriam S.C.A. trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.8% in the first quarter, HoldingsChannel reports. The firm owned 1,670,288 shares of the biopharmaceutical company’s stock after selling 161,897 shares during the period. Gilead Sciences makes up about 1.2% of Candriam S.C.A.’s portfolio, making the stock its 10th largest position. Candriam S.C.A.’s holdings in Gilead Sciences were worth $232,788,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in GILD. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC increased its position in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new position in Gilead Sciences during the 4th quarter worth approximately $26,000. Wealth Preservation Advisors LLC boosted its holdings in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new position in Gilead Sciences in the fourth quarter worth approximately $28,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 3.7%

GILD stock opened at $129.83 on Friday. Gilead Sciences, Inc. has a twelve month low of $107.75 and a twelve month high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The stock’s 50 day moving average is $129.78 and its 200-day moving average is $134.96. The firm has a market capitalization of $161.19 billion, a PE ratio of 17.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a $0.82 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Analyst Ratings Changes

Several research firms have recently commented on GILD. Royal Bank Of Canada decreased their price objective on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a report on Tuesday. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Truist Financial decreased their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday. Weiss Ratings downgraded shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Finally, Leerink Partners dropped their price objective on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Twenty-six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $159.04.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,000 shares of company stock worth $10,824,500 over the last quarter. Insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.